Progyny (NASDAQ:PGNY) Reports Upbeat Q3, Stock Soars

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Progyny’s annualized revenue growth of 10.8% over the last two years is below its five-year trend, but we still think the results were respectable.Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Luckily, ...